Quidel in flu testing deal with Roche
Quidel Corp, a US provider of rapid point-of-care diagnostic tests, has entered into an exclusive partnership to provide Switzerland-headquartered Roche Pharma AG with the QuickVue Influenza A+B rapid diagnostic test for its marketing and selling activities along with its Tamiflu (oseltamivir) antiviral for the 2007-2008 flu season in Germany. The agreement will leverage the strength and speed of the QuickVue rapid test to help characterize influenza infection along with the Tamiflu treatment to improve patient recovery time.
"Vaccination, diagnosis and treatment are the three mainstays of combating seasonal flu. This partnership with Roche and Quidel pairs two leading companies committed to promoting excellence in diagnostic testing and treatment for many patients in a wide range of facilities," said Caren Mason, chief executive of Quidel. "This is a further demonstration of our QVB (Quidel Value Build) strategy," she continued.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze